| payload |
{"created_at":"2026-04-15T06:48:56.534 {"created_at":"2026-04-15T06:48:56.534009+00:00","signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","url":"https://www.nasdaq.com/articles/mesoblast-secures-exclusive-car-msc-technology-license-stock","value":{"fp":"243a955c7e5f84d8","kind":"unusual_volume","published_at":"2026-04-15T05:51:53+00:00","source":"Nasdaq Markets","summary":"(RTTNews) - Mesoblast Limited (MESO, MSB.AX) announced the acquisition of an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform. This innovation is designed to enhance the precision and effectiveness of Mesoblast's mesenchymal lineage st","tickers":["CAR"],"title":"Mesoblast Secures Exclusive CAR-MSC Technology License; Stock Up","url":"https://www.nasdaq.com/articles/mesoblast-secures-exclusive-car-msc-technology-license-stock"}}... |